KRTAP5-4 and adenoma: In the subsequent validation phase, tested in 30 CRC, 20 adenoma and 30 healthy subjects, the combination of lncRNA breast cancer anti-estrogen resistance 4 (BCAR4) with two mRNAs (keratin-associated protein 5–4, KRTAP5-4, and melanoma antigen family A3, MAGEA3) provided the greatest predictive ability, with an AUC of 0.877.